ArticleBiomacromolecules2012
Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.
Article in Biomacromolecules, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.Journal of hematology & oncology · 2026Review
- Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.Advanced drug delivery reviews · 2022Review
- Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.Advanced functional materials · 2020Article
- Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface.Macromolecular bioscience · 2018Article
- Stimuli Responsive Polymeric Systems for Cancer Therapy.Pharmaceutics · 2018Review
- Article
- Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Design of smart HPMA copolymer-based nanomedicines.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- POLYMERIC BIOMATERIALS AND NANOMEDICINES.Journal of drug delivery science and technology · 2015Article
- Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.Biomaterials science · 2015Article
- Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.Advanced healthcare materials · 2015Article
- A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.Theranostics · 2015Article
- Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells.Drug delivery and translational research · 2014Article
- Macromolecular therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.ACS nano · 2014Article
- Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy.Macromolecular bioscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
High-molecular-weight, branched N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized and conjugated with Fab' fragments of the anti-CD20 antibody, 1F5. This produced multivalent conjugates with varying valency (amount of Fab' per macromolecule) targeted to the B-cell antigen CD20. The apoptotic activity of the conjugates was screened against several B-cell lymphomas with varied expression levels of CD20 (Raji, Daudi, Ramos, Namalwa, and DG-75). The multivalent conjugates had the strongest activity against cells that had the highest expression of CD20 and failed to demonstrate any measurable activity against lymphomas that did not express the antigen. Furthermore, there was an apparent dose-dependent response to treatment with multivalent conjugates. At optimal valence and concentration, the apoptotic activity of HPMA copolymer-Fab' conjugates superseded that of free anti-CD20 Ab that was hyper-cross-linked with a polyclonal, secondary Ab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.